Zhang X-Y, Wu H-B, Ling Y, Qian Z-P, Chen L. Analysis of the effect of proton pump inhibitors on the course of common COVID-19. medRxiv 2020:13 de junio. [Ref.ID 103794]

Lee SW, Ha EK, Yeniova AO, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut 2021;70:30 de julio. [Ref.ID 103733]

Doshi P, Topol E. These coronavirus trials don’t answer the one question we need to know. N Y Times (Print) 2020:22 de septiembre. [Ref.ID 103722]

Zhang PZhi L, Cai J, Lei F, Qin J-J, Xie J, Liu Y-M, Zhao Y-C, Huang X, Lin L, Xia M, Chen M-M, Cheng X, Zhang X, Guo D, Peng Y, Ji Y-X, Chen J, She Z-G, Wang Y, Xu Q, Tan R, Wang H, Lin J, Luo P, Fu S, Cai H, Ye P, Xiao B, et al.. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circulation Research 2020;126:17 de abril. [Ref.ID 103594]

Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiology 2020;5:julio. [Ref.ID 103593]

American Heart Association, Heart Failure Society of America, American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology . American Heart Association webpage 2020:. [Ref.ID 103570]

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respiratory Medicine 2020;8:11 de marzo. [Ref.ID 103569]

Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]

Nair NP, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, Bereznicki LR. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf 2017;40:597-606. [Ref.ID 101969]

Pacurariu AC, Coloma PM, Gross-Martirosyan L, Sturkenboom MC, Straus SM. Decision making in drug safety — A literature review of criteria used to prioritize newly detected safety issues. Pharmacoepidemiol Drug Saf 2017;26:327-34. [Ref.ID 101955]

Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:24 de mayo. [Ref.ID 101602]

McCarthy M. US babies born in withdrawal from opioids quadruples in nine years, study finds. BMJ 2015;350:h2313. [Ref.ID 99233]

Kimmelman J. The secret realm of phase I trials in healthy volunteers. BMJ 2015;350:h3444. [Ref.ID 99219]

Emanuel EJ, Bedarina G, Macci K, Gabler NB, Rid A, Wendler D. Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ 2015;350:h3271. [Ref.ID 99218]

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W, for the Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-35. [Ref.ID 98367]

Anónimo. Trastornos de espectro depresivo: menos medicamentos y más cuidados. Sacylite. Boletín de Informatión Terapéutica 2014:1-8. [Ref.ID 97756]

Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry 2013;170:651-9. [Ref.ID 95430]

Ramírez E, Rossignoli T, Campos AJ, Muñoz R, Zegarra C, Tong H, Medrano N, Borobia AM, Carcas AJ, Frías J. Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals . Eur J Clin Pharmacol 2013;69:97-110. [Ref.ID 94842]

Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CCM, Arisz L, Kuks PFM, Dijkgraaf MGW, Lie-A-Huen L, de Rooij SE. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol 2013;69:75-85. [Ref.ID 94841]

Herzig S, Rothberg M. Drug prophylaxis in general medical patients: does usage reflect the benefits and risks?. BMJ 2012;344:21-3. [Ref.ID 93191]